Description: A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary
Tract Malignancies in People a with Urinary Tract or GU Cancer such as
Bladder, Kidney, Testicular, Prostate, Penis, or Neuroendocrine Cancer.
Key Inclusion: muscle invasive urothelial, CT DNA +
Description: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding
the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney,
Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Study Number: A032103
NCT#: NCT05987241
Study Name: ICONIC
Cancer Stage: IV
Key Inclusion: N/A
Description: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab)
With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Study Number: A031702
NCT#: NCT03866382
Study Name: GAIN-BCG
Cancer Stage: Ta, high grade, Tis
Key Inclusion: within 120 days prior to randomization
Description: Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment
(BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC)
Came Back After Prior BCG Therapy (GAIN-BCG)
Study Number: A032303
NCT#: NCT07000084
Study Name: reCHARGE
Cancer Stage: IV
Key Inclusion: castrate resistant
Description: A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's
Choice of Therapy in Participants With Metastatic Castration-resistant
Prostate Cancer (rechARge)
